Lazard Capital Markets has upgraded Cubist Pharmaceuticals CBST from Hold to Buy and has established a $33 price target following the settlement of patent litigation with Teva Pharmaceuticals TEVA.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: UpgradesPrice TargetAnalyst RatingsBiotechnologycubist pharmaceuticalsHealth CareLazard Capital MarketsPharmaceuticalsTEVA PHARMACEUTICALS
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
